Investigation of Ki-67 and Clinical Outcome in Feline Nasal Adenocarcinoma Treated Using Hypofractionated Radiotherapy
Premkamon Aonta, Piraya Jaiyangyeun, Wutthiwong Theerapan, Supreeya Srisampan, Charuwan Wongsali, Attawit Kovitvadhi, Tassanee Jaroensong · 2024
Read Investigation of Ki-67 and Clinical Outcome in Feline Nasal Adenocarcinoma Treated Using Hypofractionated Radiotherapy by Premkamon Aonta, Piraya Jaiyangyeun, Wutthiwong Theerapan, Supreeya Srisampan, Charuwan Wongsali, Attawit Kovitvadhi, Tassanee Jaroensong (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11672515.txt.
Description
Premkamon Aonta and co-authors test a cell-growth marker in cats with nose cancer in this 2024 study. Nineteen cats with nasal adenocarcinoma received a compressed course of radiation. The marker, Ki-67, flags cells that are actively dividing, and it forecasts outcomes in human cancers.
Median survival for the group was 550 days. Cats whose tumors shrank lived far longer than those whose did not. Against expectation, cats with high Ki-67 lived longer than cats with low Ki-67, roughly a thousand days against under a year. White cell counts fell after treatment but did not track survival. The authors suggest Ki-67 may help forecast this cancer in cats, pending larger studies.
Catalog record
| CREATOR | Premkamon Aonta, Piraya Jaiyangyeun, Wutthiwong Theerapan, Supreeya Srisampan, Charuwan Wongsali, Attawit Kovitvadhi, Tassanee Jaroensong |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |